scholarly journals Scalp Metastasis as the First Sign of Small-Cell Lung Cancer: Management and Literature Review

2014 ◽  
Vol 99 (4) ◽  
pp. 325-329 ◽  
Author(s):  
Nikolaos S. Salemis ◽  
Georgios Veloudis ◽  
Kyriakos Spiliopoulos ◽  
Georgios Nakos ◽  
Nikolaos Vrizidis ◽  
...  

Abstract Cutaneous metastasis from primary visceral malignancy is a relatively uncommon clinical entity, with a reported incidence ranging from 0.22% to 10% among various series. However, the presence of cutaneous metastasis as the first sign of a clinically silent visceral cancer is exceedingly rare. We describe here a case of an asymptomatic male patient who presented with a solitary scalp metastasis as the initial manifestation of an underlying small-cell lung cancer. Diagnostic evaluation revealed advanced disease. We conclude that the possibility of metastatic skin disease should always be considered in the differential diagnosis in patients with a history of smoking or lung cancer presenting with cutaneous nodules. Physicians should be aware of this rare clinical entity, and appropriate investigation should be arranged for early diagnosis and initiation of the appropriate treatment. The prognosis for most patients remains poor.

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2110 ◽  
Author(s):  
Samira Shojaee ◽  
Patrick Nana-Sinkam

Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.


Author(s):  
Ruby Gupta ◽  
Melanie Smalley ◽  
Nwabundo Anusim ◽  
Vishal Jindal ◽  
Mandeep Singh Rahi ◽  
...  

Background: Lung cancer is one of the leading causes of cancer mortality in the US. The use of precision medicine in the past 10 years has significantly changed the therapeutic landscape of lung cancer. Management of advanced non-small cell lung cancer (NSCLC) has transitioned from a chemotherapeutic approach to targeted treatments and immunotherapeutic agents. Several tyrosine kinase inhibitors (TKIs) have been approved for patients with targeted mutations while patients who do not have driver mutations; immunotherapy has been recently approved as frontline therapy, which has resulted in marked improvement in overall survival and added a new tool in our armamentarium. Aims: The purpose of this review is to highlight recent advancements in diagnostic approach and management strategies in patients with metastatic NSCLC. Materials and methods: Published studies included in Medline (via PubMed) and National Comprehensive Cancer Network Guidelines were reviewed for data gathering. Conclusion: The use of next generation sequencing has significantly changed our understanding of molecular oncogenic mechanisms of lung cancer. These advancements have created a paradigm shift in the treatment strategies of metastatic lung cancer from primarily chemotherapeutic approach to increasing use of targeted therapies and immune check point inhibitors (ICI) leading to better survival rates and lesser toxicity.


2017 ◽  
Vol 130 (17) ◽  
pp. 2132-2133 ◽  
Author(s):  
Man Li ◽  
Tian Guan ◽  
Zhang-Lei Mu ◽  
Qian-Xi Xu ◽  
Lin Cai ◽  
...  

2017 ◽  
Vol Volume 9 ◽  
pp. 443-449 ◽  
Author(s):  
Christos Chouaid ◽  
Delphine Loirat ◽  
Emilie Clay ◽  
Aurélie Millier ◽  
Chloé Godard ◽  
...  

2019 ◽  
Vol 31 (10) ◽  
pp. 688-696 ◽  
Author(s):  
J.B. Adizie ◽  
A. Khakwani ◽  
P. Beckett ◽  
N. Navani ◽  
D. West ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document